User profiles for Sara Carazo
 | Sara CarazoInstitut national de santé publique du Québec Verified email at inspq.qc.ca Cited by 1177 |
[HTML][HTML] Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea
Background Ebola virus disease (EVD) is a highly lethal condition for which no specific
treatment has proven efficacy. In September 2014, while the Ebola outbreak was at its peak, the …
treatment has proven efficacy. In September 2014, while the Ebola outbreak was at its peak, the …
[HTML][HTML] Protection against omicron (B. 1.1. 529) BA. 2 reinfection conferred by primary omicron BA. 1 or pre-omicron SARS-CoV-2 infection among health-care …
Background There is a paucity of data on vaccine-induced or infection-induced (hybrid or
natural) immunity against omicron (B.1.1.529) subvariant BA.2, particularly in comparing the …
natural) immunity against omicron (B.1.1.529) subvariant BA.2, particularly in comparing the …
Estimated protection of prior SARS-CoV-2 infection against reinfection with the Omicron variant among messenger RNA–vaccinated and nonvaccinated individuals in …
Importance The Omicron variant is phylogenetically and antigenically distinct from earlier
SARS-CoV-2 variants and the original vaccine strain. Protection conferred by prior SARS-CoV-…
SARS-CoV-2 variants and the original vaccine strain. Protection conferred by prior SARS-CoV-…
[HTML][HTML] Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted
…, A Rodallec, G Piorkowski, S Carazo… - PLoS neglected …, 2017 - journals.plos.org
Background In 2014–2015, we assessed favipiravir tolerance and efficacy in patients with
Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been …
Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been …
Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination
Importance Omicron is phylogenetically- and antigenically-distinct from earlier SARS-CoV-2
variants and the original vaccine strain. Protection conferred by prior SARS-CoV-2 infection …
variants and the original vaccine strain. Protection conferred by prior SARS-CoV-2 infection …
Chemosensory dysfunctions induced by COVID-19 can persist up to 7 months: a study of over 700 healthcare workers
…, M Blais, S Carazo… - Chemical …, 2021 - academic.oup.com
Several studies have revealed either self-reported chemosensory alterations in large
groups or objective quantified chemosensory impairments in smaller populations of patients …
groups or objective quantified chemosensory impairments in smaller populations of patients …
2023/24 mid-season influenza and Omicron XBB. 1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)
The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24
influenza vaccine effectiveness (VE) of 63% (95% CI: 51–72) against influenza A(H1N1)pdm09, …
influenza vaccine effectiveness (VE) of 63% (95% CI: 51–72) against influenza A(H1N1)pdm09, …
[HTML][HTML] Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test …
Background Older adults (aged ≥60 years) were prioritised for COVID-19 booster vaccination
due to severe outcome risk, but the risk for this group is also affected by previous SARS-…
due to severe outcome risk, but the risk for this group is also affected by previous SARS-…
Psychological distress of healthcare workers in Québec (Canada) during the second and the third pandemic waves
Objective We aimed to measure the prevalence of psychological distress among Quebec
healthcare workers (HCWs) during the second and third pandemic waves and to assess the …
healthcare workers (HCWs) during the second and third pandemic waves and to assess the …
Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec …
Introduction In Canada, first and second doses of mRNA vaccines against SARS-CoV-2
were uniquely spaced 16 weeks apart, but the duration of single-dose protection remains …
were uniquely spaced 16 weeks apart, but the duration of single-dose protection remains …